Key result
Ivabradine successfully treated a 3-year-old girl with congenital junctional ectopic tachycardia that was resistant to conventional antiarrhythmic medications.
Why the study?
Does ivabradine improve congenital junctional ectopic tachycardia in a pediatric patient resistant to conventional medications?
Case Report (n=1)
Does ivabradine improve congenital junctional ectopic tachycardia in a pediatric patient resistant to conventional medications?
Ivabradine may serve as a novel therapeutic option for congenital junctional ectopic tachycardia resistant to conventional antiarrhythmic medications.
Answers are grounded in this paper and cite their sources.
May support ivabradine in refractory pediatric congenital JET; hypothesis-generating and requires prospective trials.
Ivabradine is a new antiarrhythmic agent with direct inhibition of the pacemaker (If) current. It has been used extensively to decrease sinus rate in the treatment of cardiac failure, and also in a single case of atrial ectopic tachycardia in a child. Here we report the case of a 3-year-old girl with congenital junctional ectopic tachycardia (JET), resistant to conventional antiarrhythmic medications, who was successfully treated with ivabradine. We suggest that ivabradine can be an effective treatment for junctional automatic tachycardias and can be considered as a new line of therapy for this incessant form of tachycardia.
No takes yet. Share an insight, caveat, or question.
Alghamdi et al. (2012) conducted a case report in Congenital junctional ectopic tachycardia (n=1). Ivabradine was evaluated on Successful treatment of tachycardia. Ivabradine successfully treated a 3-year-old girl with congenital junctional ectopic tachycardia that was resistant to conventional antiarrhythmic medications.
Synapse has enriched 10 related papers. Consider them for comparative context: